Chest Medicine
Covid: Masks upgrade cuts infection risk, research finds.
30 Jun, 2021 | 10:16h | UTCCovid: Masks upgrade cuts infection risk, research finds – BBC
Pulmonary embolism in patients with COVID-19: incidence, risk factors, clinical characteristics, and outcome.
30 Jun, 2021 | 10:13h | UTC
Consensus Statement: The role of lung ultrasound in COVID-19 disease.
30 Jun, 2021 | 10:12h | UTCThe role of lung ultrasound in COVID-19 disease – Insights into Imaging
Should I get my second AstraZeneca dose? Yes, it almost doubles your protection against Delta.
30 Jun, 2021 | 10:11h | UTCRelated: Effectiveness of COVID-19 vaccines against the B.1.617.2 variant – medRxiv
M-A: The utility of the rapid shallow breathing index in predicting successful extubation – “As a stand-alone test, the RSBI has moderate sensitivity and poor specificity for predicting extubation success”.
30 Jun, 2021 | 10:07h | UTCThe Utility of the Rapid Shallow Breathing Index in Predicting Successful Extubation: A Systematic Review and Meta-analysis – CHEST (link to abstract – $ for full-text)
IHME COVID-19 model has been updated for over 200 world locations.
29 Jun, 2021 | 10:13h | UTCCOVID-19 Projections – Institute for Health Metrics and Evaluation
Video: Insights from IHME’s latest COVID-19 model update
Commentary on Twitter
📣 NEW ✨ Our COVID-19 model has been updated for over 200 world locations 🌎 🌍 🌏 📊 (https://t.co/5biAggRz1T)
📺 Full video: https://t.co/wLGeAiiYhy
📄 PDFs with explanations of country-specific projections: https://t.co/9KQxWwhQqx pic.twitter.com/8sSEzyXEf8— Institute for Health Metrics and Evaluation (IHME) (@IHME_UW) June 27, 2021
Phase 1/2 RCT: CoronaVac is well tolerated and safe and induces strong humoral responses in children and adolescents aged 3–17 years.
29 Jun, 2021 | 10:09h | UTCInvited commentary: COVID-19 vaccines for children younger than 12 years: are we ready? – The Lancet Infectious Diseases
Commentary on Twitter
NEW—A phase 1/2 clinical trial of #CoronaVac in 550 children and adolescents aged 3-17 years in China suggests two doses of the vaccine are safe and generate a strong antibody response. Read in @TheLancetInfDis: https://t.co/eXSagRu1Cs pic.twitter.com/fOKNLUjNwc
— The Lancet (@TheLancet) June 28, 2021
SARS-CoV-2 mRNA vaccines induce persistent human germinal center responses, suggesting immunity will be long-lasting.
29 Jun, 2021 | 10:03h | UTCSARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses – Nature
Commentaries: Immune response to FDA-approved vaccines is strong and potentially long-lasting – News Medical
Commentary on Twitter (thread – click for more)
Just published @nature
A bonus factor after covid vaccination: germinal center factories for durable, antigen-specific, B cells and plasmoblasts induced by mRNA vaccination, as determined by lymph node aspirates from vaccinees https://t.co/5eR0gDSWHq
@TheBcellArtist @WUSTLmed pic.twitter.com/C5xPSrh5Gw— Eric Topol (@EricTopol) June 28, 2021
Case report: Thrombosis with Thrombocytopenia After the Messenger RNA–1273 Vaccine.
29 Jun, 2021 | 10:07h | UTCThrombosis With Thrombocytopenia After the Messenger RNA–1273 Vaccine – Annals of Internal Medicine
[Preprint] 3rd AstraZeneca shot gives strong immunity.
29 Jun, 2021 | 10:01h | UTCStudy: 3rd AstraZeneca shot gives strong immunity – Reuters
Original Study (preprint): Tolerability and Immunogenicity After a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 (AZD1222) – SSRN/The Lancet
Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials – “IVM did not reduce all-cause mortality, length of stay or viral clearance in RCTs in COVID-19 patients with mostly mild disease”.
29 Jun, 2021 | 10:00h | UTC
Phase 2 RCT: Immunogenicity and reactogenicity of a Pfizer-BioNTech booster in patients that have received a single dose of AstraZeneca vaccine – “BNT162b2 (Pfizer) given as a second dose in individuals prime vaccinated with ChAdOx1-S (AstraZeneca) induced a robust immune response, with an acceptable and manageable reactogenicity profile”.
28 Jun, 2021 | 10:01h | UTCCommentaries: Heterologous vaccine regimens against COVID-19 – The Lancet AND
Commentary on Twitter (thread – click for more)
NEW #COVID19 research—Phase 2 trial by @borobia_am, @antoniojcarcas
et al. reports BNT162b2 given as a 2nd dose in individuals prime vaccinated with ChAdOx1-S induced a robust immune response, with an acceptable and manageable reactogenicity profile. Read https://t.co/muL0XQxdjG. pic.twitter.com/BxPlXB8EF7— The Lancet (@TheLancet) June 26, 2021
WHO urges fully vaccinated people to continue to wear masks as delta Covid variant spreads.
28 Jun, 2021 | 09:55h | UTCWHO urges fully vaccinated people to continue to wear masks as delta Covid variant spreads – CNBC
Commentary on Twitter (thread – click for more)
⚠️WEAR MASK EVEN IF VACCINATED—Top @WHO leader urges masks against #DeltaVariant even if 2-dose vaxxed. "Vaccine alone won't stop community transmission. People need to use masks consistently, be in ventilated spaces—even if you're vaccinated" #COVID19🧵https://t.co/qPZTmcy9iW pic.twitter.com/j5V6fbHdoi
— Eric Feigl-Ding (@DrEricDing) June 26, 2021
Delta “Plus”: Scientists say too early to tell risk of Covid-19 variant.
28 Jun, 2021 | 09:53h | UTCDelta plus India: Scientists say too early to tell risk of Covid-19 variant – BBC
Perspective | Is one vaccine dose enough if you’ve had COVID? What the science says.
28 Jun, 2021 | 09:52h | UTCIs one vaccine dose enough if you’ve had COVID? What the science says – Nature
Commentary on Twitter
One vaccine dose for prior covid: @ElieDolgin reviews the recent data @Nature https://t.co/amJ4RcGtuW
Vaccination cards/proof should be modified here to equate prior covid as the 1st dose and not force people to get an unnecessary 2nd dose— Eric Topol (@EricTopol) June 27, 2021
Study finds 96.1% of patients objectively recovered from anosmia 1 year after COVID-19 diagnosis.
28 Jun, 2021 | 09:49h | UTCClinical Outcomes for Patients With Anosmia 1 Year After COVID-19 Diagnosis – JAMA Network Open
Commentary: Did Covid-19 take your taste and smell? Here’s when they may return – CNN AND Lost Sense of Smell Returns for Almost All COVID Survivors – HealthDay
WHO: Delta variant is ‘most transmissible’ identified so far.
28 Jun, 2021 | 09:58h | UTCWHO: Delta variant is ‘most transmissible’ identified so far – Associated Press
Related: Delta COVID variant fuels global surges, complicates reopenings – CIDRAP AND Delta variant triggers dangerous new phase in the pandemic – Science AND Delta coronavirus variant: scientists brace for impact – Nature AND Rapid displacement of SARS-CoV-2 variant B.1.1.7 by B.1.617.2 and P.1 in the United States – medRxiv AND COVID-19: The rise and rise of Delta – Sciblogs AND Increased transmissibility and global spread of SARS-CoV-2 variants of concern – “Estimated transmissibility increases of alpha 29% (95% CI: 24–33), beta 25% (95% CI: 20–30), gamma 38% (95% CI: 29–48) & delta 97% (95% CI: 76–117)”.
IDSA Updated Covid-19 Guidance: Co-Infection and Antimicrobial Stewardship – “bacterial coinfections with SARS-CoV-2 infection are relatively infrequent (likely occurring in less than 10% of hospitalized COVID-19 patients)”.
28 Jun, 2021 | 09:51h | UTCCo-Infection and Antimicrobial Stewardship – Infectious Diseases Society of America
[Preprint] Long Covid: Third of people infected have long term symptoms.
25 Jun, 2021 | 10:30h | UTCCovid-19: Third of people infected have long term symptoms – The BMJ
Original study (preprint): Persistent symptoms following SARS-CoV-2 infection in a random community sample of 508,707 people – Imperial College London
Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis.
25 Jun, 2021 | 10:37h | UTC
Commentary on Twitter
#COVID19 Associated Pulmonary Aspergillosis
🍄increasing, associated with excess mortality
🍄complex: colonization + tissue/angio-invasion
🍄diagnose? bronchoscopy/BAL
🍄antifungals recommended
🍄consider discontinuating/tapering steroids in no respondershttps://t.co/HhS6wUfibn pic.twitter.com/CJwE3CEXxn— Intensive Care Medicine (@yourICM) June 23, 2021
No evidence yet to suggest Covid vaccine booster is needed, CDC group says.
25 Jun, 2021 | 10:29h | UTCNo evidence yet to suggest Covid vaccine booster is needed, CDC group says – NBC News
Related opinion: 7 Reasons Why We Should Not Need Boosters for COVID-19 – by Monica Ghandi, MD
Long Covid: Half of young adults with COVID-19 have persistent symptoms 6 months after, study finds.
25 Jun, 2021 | 10:33h | UTCOriginal Study: Long COVID in a prospective cohort of home-isolated patients – Nature Medicine
Commentary on Twitter
Analysis of a prospectively enrolled cohort of patients with #SARSCoV2 infections reveals a high proportion who experienced #LongCovid symptoms at 6 months, despite being relatively young and having only mild to moderate acute #COVID19 symptoms https://t.co/fuW2QpfJog
— Nature Medicine (@NatureMedicine) June 23, 2021
Delta COVID variant fuels global surges, complicates reopenings.
25 Jun, 2021 | 10:23h | UTCDelta COVID variant fuels global surges, complicates reopenings – CIDRAP
Perspective | Why are people with obesity more vulnerable to COVID?
25 Jun, 2021 | 10:21h | UTCWhy Are People with Obesity More Vulnerable to COVID? – Scientific American
Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients can improve the immunogenicity of the vaccine.
24 Jun, 2021 | 10:32h | UTC